The All Wales Medicines Strategy Group started the assessment of ivacaftor (Kalydeco) as soon as the drug company formally engaged with the appraisal process. This process is recognised to be robust and normally takes about 21 weeks to allow all parties, including patient organisations such as the Cystic Fibrosis Trust, to submit their comments. The final appraisal decision for Kalydeco is scheduled to be reached at a public meeting on 8th May 2013.
More top news
On tonight's Wales at Six, we speak to the Grandad who's the first in the UK to have his rib cage rebuilt using 3D technology.
A quiet start to the night but the cloud will thicken ahead of a band of drizzly rain which will sink southwards by the early hours.
One of literature's most loved and celebrated characters appear on new 50p coins released today for a limited period of time.